Altered Urinary Excretion of Human Kininase Activity in Acute Myocardial Infarction

Greco, Aldo V.; Porcelli, G; Rebuzzi, Antonio Giuseppe; Jorio, M.; Ranieri, M.; Ranalli, L.

doi:10.1007/978-1-4757-0926-1_55

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The renal kallikrein-kinin system has been shown to regulate kidney haemodynamics [12][13][14] by modulating such parameters as blood pressure, blood flow, renal vascular resistance and capillary permeability [15]. Decreased kallikrein excretion in Type 2 (non-insulin-dependent) diabetic patients with hypertension and nephropathy [16,17] and elevated urinary kallikrein concentration in patients with poorly-controlled Type 1 diabetes has been reported [18]. Moreover, different reports have shown that untreated streptozotocin diabetic rats show a reduced synthesis and excretion of active renal kallikrein [19][20][21].…”

mentioning

confidence: 99%

Urinary kallikrein excretion in Type 1 (insulin-dependent) diabetes mellitus

et al. 1993

Self Cite

View full text Add to dashboard Cite

Kidney haemodynamics appear to change after the early phases of diabetic nephropathy: increases in glomerular filtration rate and in renal plasma flow have been widely reported, while kidney size is increased. As the renal kallikrein-kinin system has been demonstrated to regulate kidney blood circulation, we have evaluated the excretion of urinary kallikrein in 87 Type 1 (insulin-dependent) diabetic patients with and without hyperfiltration. Urinary kallikrein excretion was measured in 24-h urine collections. The esterolytic activity was determined by fluorimetric assay. The excretion of urinary kallikreins was significantly higher in hyperfiltering patients (472 +/- 125 esterase units/24 h) than in normofiltering (168 +/- 77 esterase units/24 h) and control subjects (151 +/- 39 esterase units/24 h), p < 0.001. Furthermore, we observed a positive correlation between urinary kallikrein excretion and glomerular filtration rate (r = 0.785). These data suggest that variations of kallikrein and kinin concentrations may play a role in the alteration of renal haemodynamics in Type 1 diabetes. It is possible that the kinin-kallikrein system, the renin-angiotensin system and the prostaglandins may interact to determine the haemodynamic alterations which are present in the diabetic disease.

show abstract

mentioning

confidence: 99%

Urinary kallikrein excretion in Type 1 (insulin-dependent) diabetes mellitus

et al. 1993

Self Cite

View full text Add to dashboard Cite

show abstract

“…Assessment of toxic effects and response CRS and ICANS were graded according to the ASTCT consensus 47 . Other toxicities during and after therapy were assessed according to the National Institutes of Health Common Terminology Criteria for Adverse Events Version 5.0 (http://ctep.cancer.gov/).…”

Section: Trial Design and Oversightmentioning

confidence: 99%

Efficacy-enhanced and cytokine release syndrome-attenuated anti-CD7 universal chimeric antigen receptor-T cell therapy for relapsed/refractory CD7-positive hematological malignancies: A phase I clinical study

Huang¹,

Hu²,

Zhou³

et al. 2021

Preprint

View full text Add to dashboard Cite

Chimeric antigen receptor-T cell (CAR-T) therapy in T cell malignancies faces fratricide, T cell aplasia, and product contamination. Here, we successfully developed a universal anti-CD7 CAR-T product (RD13-01). RD13-01 contains a bbzg-CAR comprising an anti-CD7 single-chain variable fragment, a 4-1BB costimulatory domain, a CD3ζ signaling domain, the intracellular domain of the common γ chain, and a natural killer cell inhibitory molecule (E-cadherin). TRAC, CD7 and HLA-II were disrupted to avoid graft versus host disease (GvHD), fratricide and rejection. Bbzg-CAR-T exerted antitumor effects superior to those of conventional CAR-T, while exhibiting reduced cytokine production. Among 11 evaluable relapsed/refractory (r/r) patients, no dose-limited toxicity, GvHD, immune effector cell-associated neurotoxicity or severe cytokine release syndrome (grade≥3) occurred. Nine (82%) showed objective response. For r/r leukemia and NHL, complete response rates were 75% and 33.3% respectively. Outstanding safety and efficacy of this universal CAR-T product was achieved in CD7+ T cell malignancies.

show abstract

Altered Urinary Excretion of Human Kininase Activity in Acute Myocardial Infarction

Cited by 2 publications

References 5 publications

Urinary kallikrein excretion in Type 1 (insulin-dependent) diabetes mellitus

Urinary kallikrein excretion in Type 1 (insulin-dependent) diabetes mellitus

Efficacy-enhanced and cytokine release syndrome-attenuated anti-CD7 universal chimeric antigen receptor-T cell therapy for relapsed/refractory CD7-positive hematological malignancies: A phase I clinical study

Contact Info

Product

Resources

About